Editorial: To Treat or Not to Treat: The Use of HRT in Patients With Ovarian Cancer

JCO open access

 Few studies have addressed the issue of HRT in women with EOC.

 The surgical treatment of epithelial ovarian cancer (EOC) results in the abrupt induction of menopause in pre- and perimenopausal women, who account for approximately 20% of all patients with ovarian cancer.¹ The loss of ovarian estrogen results in disruptive vasomotor symptoms, which can negatively affect quality of life.......In the article that accompanies this editorial, Eeles et al¹⁶ present the results of a long-awaited multinational, randomized, nonblinded phase III trial of HRT in pre- and postmenopausal women receiving a recent diagnosis of EOC.....

Eeles et al:  The primary end point for this study was overall survival (OS), and the main secondary end point was relapse-free survival (RFS). Other specified secondary end points were compliance with HRT, myocardial infarction, fracture, transient ischemic attack, cerebrovascular accident, and second cancer.....The trial was closed early as a result of difficulty in accruing the 570 patients projected for the OS .analysis. 
 

• See accompanying article doi:10.1200/JCO.2015.60.9719

Previous Section

REFERENCES

1. 1.↵
   1. National Cancer Institute

   SEER stat fact sheets: Ovary cancer. http://seer.cancer.gov/statfacts/html/ovary.html.
2. 2.↵
   1. Colditz GA,
   2. Willett WC,
   3. Stampfer MJ,
   4. et al.

   (1987) Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105–1110.

   CrossRefMedlineGoogle Scholar
3. 3.↵
   1. Richelson LS,
   2. Wahner HW,
   3. Melton LJ III,
   4. et al.

   (1984) Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273–1275.

   CrossRefMedlineGoogle Scholar
4. 4.↵
   1. Coope J,
   2. Thomson JM,
   3. Poller L

   (1975) Effects of “natural oestrogen” replacement therapy on menopausal symptoms and blood clotting. BMJ 4:139–143.

   Abstract/FREE Full Text
5. 5.↵
   1. Horsman A,
   2. Gallagher JC,
   3. Simpson M,
   4. et al.

   (1977) Prospective trial of oestrogen and calcium in postmenopausal women. BMJ 2:789–792.

   Abstract/FREE Full Text
6. 6.↵
   1. Sieh W,
   2. Kobel M,
   3. Longacre TA,
   4. et al.

   (2013) Hormone-receptor expression and ovarian cancer survival: An Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14:853–862.

   CrossRefMedlineGoogle Scholar
7. 7.↵
   1. Simpkins F,
   2. Garcia-Soto A,
   3. Slingerland J

   (2013) New insights on the role of hormonal therapy in ovarian cancer. Steroids 78:530–537.

   CrossRefMedlineGoogle Scholar
8. 8.↵
   1. Hein A,
   2. Thiel FC,
   3. Bayer CM,
   4. et al.

   (2013) Hormone replacement therapy and prognosis in ovarian cancer patients. Eur J Cancer Prev 22:52–58.

   CrossRefMedlineGoogle Scholar
9. 9.↵
   1. Chlebowski RT,
   2. Anderson GL,
   3. Gass M,
   4. et al.

   (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692.

   CrossRefMedlineGoogle Scholar
10. 10.↵
    1. Chlebowski RT,
    2. Aragaki AK,
    3. Anderson GL

    (2015) Menopausal hormone therapy influence on breast cancer outcomes in the Women's Health Initiative. J Natl Compr Canc Netw 13:917–924.

    Abstract/FREE Full Text
11. 11.↵
    1. Chlebowski RT,
    2. Kuller LH,
    3. Prentice RL,
    4. et al.

    (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587.

    CrossRefMedlineGoogle Scholar
12. 12.↵
    1. LaCroix AZ,
    2. Chlebowski RT,
    3. Manson JE,
    4. et al.

    (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 305:1305–1314.

    CrossRefMedlineGoogle Scholar
13. 13.↵
    1. Eeles RA,
    2. Tan S,
    3. Wiltshaw E,
    4. et al.

    (1991) Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302:259–262.

    Abstract/FREE Full Text
14. 14.↵
    1. Ursic-Vrscaj M,
    2. Bebar S,
    3. Zakelj MP

    (2001) Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: The effect on survival. Menopause 8:70–75.

    CrossRefMedlineGoogle Scholar
15. 15.↵
    1. Guidozzi F,
    2. Daponte A

    (1999) Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 86:1013–1018.

    CrossRefMedlineGoogle Scholar
16. 16.↵
    1. Eeles RA,
    2. Morden JP,
    3. Gore M,
    4. et al.

    Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the adjuvant hormone therapy randomized trial. J Clin Oncol, doi: 10.1200/JCO.2015.60.9719.
17. 17.↵
    1. Powles TJ,
    2. Ashley S,
    3. Tidy A,
    4. et al.

    (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290.

    Abstract/FREE Full Text
18. 18.↵
    1. Davies C,
    2. Pan H,
    3. Godwin J,
    4. et al.

    (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816.

    CrossRefMedlineGoogle Scholar